Universal Beteiligungs und Servicegesellschaft mbH Trims Holdings in Illumina, Inc. $ILMN

Universal Beteiligungs und Servicegesellschaft mbH reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 192,296 shares of the life sciences company’s stock after selling 15,739 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Illumina were worth $25,323,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Optas LLC increased its stake in shares of Illumina by 154.4% during the fourth quarter. Optas LLC now owns 5,747 shares of the life sciences company’s stock valued at $754,000 after purchasing an additional 3,488 shares in the last quarter. Jones Kertz & Associates Inc. purchased a new stake in shares of Illumina in the 4th quarter worth approximately $419,000. Evergreen Capital Management LLC increased its position in Illumina by 13.5% during the 4th quarter. Evergreen Capital Management LLC now owns 5,531 shares of the life sciences company’s stock valued at $725,000 after buying an additional 658 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in Illumina during the fourth quarter valued at $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Illumina by 11.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 49,684 shares of the life sciences company’s stock worth $6,517,000 after acquiring an additional 5,248 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by company insiders.

Illumina Price Performance

Shares of ILMN opened at $125.44 on Friday. The company has a market capitalization of $19.06 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The firm has a 50 day moving average of $124.88 and a 200 day moving average of $125.43. Illumina, Inc. has a twelve month low of $73.86 and a twelve month high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 5.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ILMN shares. Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 14th. Evercore set a $150.00 target price on shares of Illumina in a report on Friday, February 6th. UBS Group reiterated a “neutral” rating and set a $135.00 price target on shares of Illumina in a report on Friday, February 6th. Piper Sandler reduced their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Finally, TD Cowen reissued a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and an average price target of $129.69.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.